Skeptic critique for analysis AD-MASTER-PLAN-BDNF-20260428030755: AD Master Plan preregistration: BDNF
The analysis question is substantive, but the current record does not by itself prove the claim. The main dissent is: neurotrophic rescue may improve plasticity markers without interrupting amyloid or tau-driven degeneration.
The debate should reject overclaiming in three forms. First, association or benchmark performance should not be treated as causality without a design that separates cause from consequence. Second, a positive average effect can hide subgroup failure across BDNF, AD, tau, amyloid. Third, an analysis that lacks provenance, environment capture, or preregistered endpoints can produce plausible but non-reproducible conclusions.
A decisive falsifier would be failure of deliver BDNF-pathway activation in hippocampal circuit models and test synaptic function before tau-mediated degeneration to move the predicted proximal endpoint under adequate power and controls. The strongest alternative explanation is that the observed signal is a disease-stage marker, prompt or notebook artifact, or compensatory response rather than an upstream driver.